C ongenital heart defects (CHDs) are the most common congenital anomaly, occurring in approximately 6-10 infants per 1000 live births. [1] [2] [3] [4] [5] Although advances in surgery have improved outcomes for term and near-term infants with CHDs, for those born very prematurely (28-32 weeks' gestational age [GA]) or extremely prematurely (<28 weeks GA), neonatal heart surgery is often infeasible or associated with excess risk. 6 Therefore, consideration of cardiac intervention is typically delayed to allow these infants to grow and develop. During this time, they are exposed to physiologic derangements inherent to both their prematurity and CHD. 7, 8 These derangements may cause death or major morbidities that preclude the possibility of intervention. 7, 8 Despite recognition that premature infants with CHDs are a very vulnerable population, little is known about the epidemiology or outcomes of very/extremely premature infants with CHDs. Prior epidemiologic studies have largely focused on term infants. Similarly, prior multicenter analyses evaluating the association between GA and mortality in infants with CHDs have all focused on either infants born at term (37-40 weeks completed GA) or late preterm (34-37 weeks GA). [9] [10] [11] Studies evaluating very/extremely premature infants with CHDs are generally small (n < 300) and encompass a limited variety of defects. [12] [13] [14] [15] [16] To better understand the epidemiology and outcomes of very/extremely premature infants with CHDs, we used a large, nationally representative administrative database to determine the birth prevalence of CHDs across the spectrum of common defects in very/extremely premature infants, and to compare mortality between premature infants with and without CHDs.
ASDs
Atrial septal defects CHDs Congenital heart defects DORV Double outlet right ventricle GA Gestational age HLHS Hypoplastic left heart syndrome ICD-9-CM Neonates born at <25 weeks GA were excluded because of the high mortality rates related to being born at such extremes of prematurity. 17, 18 Term birth was defined as any birth hospitalization that did not have a prematurity or post-maturity related ICD-9-CM diagnosis. CHDs were classified using ICD-9-CM codes for the various defects. Hypoplastic left heart syndrome (HLHS) included ICD-9-CM codes for mitral atresia and HLHS. A subset of severe CHDs were defined consistent with previous studies and included atrioventricular canal defects, truncus arteriosus, total anomalous pulmonary venous return, tetralogy of Fallot, pulmonary atresia, tricuspid atresia, HLHS, Ebstein anomaly, aortic stenosis, transposition of the great arteries, coarctation, double outlet right ventricle (DORV), and interrupted aortic arch (IAA). 4, 19 These are all CHDs that would be expected to be nearly universally diagnosed during a prolonged neonatal hospital stay, which is expected for very and extremely premature neonates. Patent ductus arteriosus was not included when calculating CHD birth prevalence. For epidemiologic analyses, defects were not mutually exclusive and infants with multiple defects could be counted in several diagnostic categories. However, when determining the overall prevalence of CHD, each hospitalization was only counted once.
For outcomes assessments, the cohort was limited to hospitalizations in children's hospitals or pediatric units in the 2003, 2006 , and 2009 KIDs for infants less than 1 month of age (ie, not just birth hospitalizations). The 2012 KID was not used because this database does not have information on pediatric hospital or unit type. The outcomes cohort was limited to children's hospitals and pediatric units to ensure outcomes were representative of infants receiving advanced care and to prevent erroneously capturing a positive outcome (ie, survival) for infants who were born in community hospitals and immediately transferred following diagnosis of their CHD to tertiary care centers. Hospitalizations containing a diagnosis code for noncardiac fatal anomalies including trisomy 13, trisomy 18, anencephaly, and renal agenesis were excluded. For the outcomes analysis, it was important to attribute outcomes to the appropriate diagnostic category. Thus, a hierarchy of defects (Table II; available at www.jpeds.com) was created and outcomes for these hospitalizations were attributed to the highest risk defect in the hierarchy. Small for GA (SGA), Down syndrome, and DiGeorge syndrome were defined by ICD-9-CM codes.
Statistical Analyses
Primary outcomes included birth prevalence of CHDs in premature infants, calculated as number of infants with CHD per 1000 births, and in-hospital mortality. Summary statistics were used to describe patient characteristics. Weighted c 2 and t tests were performed where appropriate. Weighted multivariable logistic regression was used to calculate aORs of mortality between very and extremely premature infants with and without CHD. For this analysis, neonates with CHD were assigned a single diagnosis based on our noted hierarchy of CHD diagnoses (Table II) . In addition to diagnostic cohort, other model covariates were chosen a priori to represent a set of variables that were considered clinically relevant and included race, sex, GA in weeks, year, and the dichotomous variables: SGA status and hospital teaching status. For regression analysis, CHDs with a sample size <30 were excluded to avoid misinterpreting the data. Diagnoses of tricuspid atresia and common ventricle were combined into a category called non-HLHS single ventricle. Statistical significance was defined as a P value of less than .05. All statistical analysis was performed in SAS v 9.3 (SAS Institute, Cary, North Carolina).
Results
An estimated 249 011 infants were born between 25 and 32 weeks GA, of which 28 806 (116 per 1000 birth hospitalizations of very/extremely premature infants) had CHDs. Of those infants with CHDs, 48.6% were female and 5.9% were SGA (Table III) . Table IV summarizes the birth prevalence of various CHDs. Atrial septal defects (ASDs) were the most commonly diagnosed defect followed by ventricular septal defects (VSDs) and pulmonary stenosis. Severe CHDs had an aggregate birth prevalence of 7.4 (95% CI 6.9, 7.9) per 1000 at-risk births, significantly higher than the birth prevalence in term neonates (1.5/ 1000 term birth hospitalizations, P < .001). HLHS was the most common severe CHD followed by tetralogy of Fallot and coarctation of the aorta. The Figure ( available at www.jpeds.com) compares birth hospitalization prevalence between very/ extremely premature and term infants; 13 out of 14 defects had higher odds of diagnosis in very/extremely premature infants vs term infants, but there was wide variability by defect with unadjusted OR ranging from 6.2 for HLHS to 2.3 for transposition of the great arteries. Total anomalous pulmonary venous return had an OR of 0.3. In aggregate the birth prevalence of severe defects was significantly higher for infants born more prematurely (8.8 at 25-26 weeks GA vs 6.7 at 31-32 weeks per 1000 birth hospitalizations, P = .005). There was no significant change in birth prevalence by GA for any single severe defect; however, these analyses were underpowered. For the outcomes assessment, we restricted the cohort to a subset of 49 893 hospitalizations for very/extremely premature infants in children's hospitals or pediatric units of which 7060 (14%) had CHDs. Of these, 87 (1%) were excluded because they were associated with a diagnostic code for a lethal genetic syndrome or noncardiac anomaly. The CHD cohort was significantly more likely to be born at earlier GAs when compared with very/extremely premature infants without CHDs (18.3% vs 13.3% at 25-26 weeks, 23.5% vs 17.4% at 27-28 weeks, 26.1% vs 24.7% at 29-30 weeks GA, 32.2 vs 44.6% at 31-32 weeks GA; P < .001), have a diagnosis of Down syndrome (1.4 vs 0.1%; P < .001), and be born SGA (5.8% vs 4.3%; P < .001). Otherwise very/extremely premature infants with and without CHDs were similar.
Collectively very/extremely premature infants with severe CHDs had a 26.3% in-hospital mortality rate vs 5.3% for very/ extremely premature infants without CHDs (P < .001) and 10.9% for term neonates with severe CHDs (P < .001). However, there was a wide distribution by defect. For severe defects mortality rates ranged from 12% for coarctation of the aorta to 67% for truncus arteriosus. Simpler defects, such as ASDs and VSDs, had mortality rates (4% and 5%, respectively) that were similar to those seen for very/extremely premature infants without CHD (Table V) . In multivariable analysis, very/ extremely premature infants with severe CHDs had a 7.5-fold higher adjusted odds of death (95% CI 5.9, 9.6) than those without CHDs and a 3.4-fold (95% CI 2.8, 4.1) higher adjusted odds of death than term infants with severe defects after controlling for race, sex, GA, year, SGA status, and hospital teaching status. Of those severe defects with adequate numbers for evaluation, all except IAA had significantly higher odds of dying in the hospital compared with very/extremely premature infants without CHDs (Table V) . Specifically, DORV, pulmonary atresia, HLHS, non-HLHS single ventricle, and TOF had the highest increase in odds of in-hospital mortality. Numbers for defect-specific mortality comparisons were insufficient for truncus arteriosus, aortic stenosis, D-transposition, Ebstein anomaly, and total anomalous pulmonary venous return. There was no difference in odds of death for very/extremely premature infants with VSDs, and those with ASDs or pulmonary stenosis had significantly lower odds of dying in the hospital compared with infants without CHDs (aOR 0.60, 95% CI 0.49, 0.73 for ASD and 0.45, 95% CI 0.22, 0.93 for pulmonary stenosis).
Discussion
In this analysis of very and extremely premature infants born 25-32 weeks GA, the overall birth prevalence of CHDs (116/1000 births of similar GA) was significantly higher than the reported birth prevalence of CHDs in term neonates (6-10/1000 births). [1] [2] [3] [4] [5] Importantly, the subset of severe CHDs were almost 5-fold more likely in very/extremely premature neonates when compared with term neonates, and very/extremely premature neonates with severe CHDs had a more than 7-fold increased odds of mortality when compared with very/ extremely premature neonates without CHD.
The overall high prevalence of CHDs in very/extremely premature infants is partly driven by a high prevalence of ASDs, which are undoubtedly more commonly diagnosed in premature infants because of the increased likelihood of receiving an echocardiogram. [1] [2] [3] [4] [5] However, echocardiography utilization practices should minimally impact the prevalence of severe CHDs as these defects would be expected to be almost universally diagnosed during the neonatal period. In our cohort, the birth prevalence of severe defects in very/ extremely premature infants was 7.4/1000 birth hospitalizations compared with 1.5/1000 birth hospitalizations in term infants. Other epidemiologic studies of severe CHDs in term infants have reported slightly higher prevalence than our analysis (~2 per 1000 live births). 4, 19 It is possible that we underestimated the true birth prevalence of severe CHDs in term infants as we restricted the analysis to birth hospitalizations. Nonetheless, these relatively smaller differences would not change our overall conclusion that severe CHDs are strongly associated with very/extremely premature birth. This conclusion is consistent with the findings of Laas et al 20 who demonstrated that European children with CHDs (excluding ASD and patent ductus arteriosus) were twice as likely to be born prematurely (<37 weeks GA) or very/extremely prematurely (<32 weeks GA) than children without CHDs. Importantly, in our analysis, the relative prevalence of severe CHDs was even higher at earlier GAs.
We also found wide variation in the odds of having individual defects when comparing premature and term infants. Again there are similarities between our data and the findings of Laas et al 20 who demonstrated that the subset of single ventricle anomalies were most strongly associated with preterm birth, whereas pulmonary venous anomalies were the only defects with higher birth prevalence in term neonates. Interestingly, we also found that pulmonary venous anomalies were more common in term neonates, and we had adequate sample size to look at specific subsets of single ventricle anomalies, finding that HLHS was most strongly associated with very/ extreme premature birth. It is not clear why these differences exist, but we speculate that they reflect differences in each defect's impact on fetal physiology.
Few studies have examined mortality of very and extremely premature infants across the spectrum of CHDs. As expected, these infants had markedly higher in-hospital mortality rates compared with those without CHDs (aOR of mortality = 7.5). The overall mortality rate of 26.3% that we report is actually lower than the 44%-55% in-hospital mortality rates reported in 2 previous database studies focused on very low birth weight neonates (<1500 g) with severe CHDs.
12,21 Some of these differences may reflect that our study included patients with birth weight >1500 g and that our outcomes analysis was restricted to a subset of hospitals with more experience caring for children with heart disease (ie, excluding community hospitals). It should be noted that all of these studies (including ours) report in-hospital mortality rates only and, therefore, will underestimate infant mortality related to CHDs. Despite this, it is clear that severe CHDs are an important risk factor for mortality with odds of mortality varying from approximately 3-fold higher for the arch anomalies (coarctation and IAA) to greater than 10-fold higher for more complex defects (DORV, single ventricle defects, and pulmonary atresia). Unexpectedly, we found that having a diagnosed ASD or pulmonary stenosis was associated with improved survival. This finding requires further study. Plausibly one could speculate that ASDs might offer a survival benefit in very/extremely premature infants with pulmonary hypertension. However, this hypothesis is contrary to several prior reports suggesting that larger ASDs actually exacerbate underlying chronic lung disease of prematurity. 22, 23 It is unclear why isolated pulmonary stenosis may confer an improvement in survival. An alternate hypothesis is that there is a survival bias in our study as the most critically ill preterm neonates, including those that cannot be successfully resuscitated in the delivery room, may not undergo echocardiography.
When evaluating mortality by GA for severe CHD, greater prematurity was associated with markedly higher mortality (40% at 25-26 weeks GA vs 22% at 31 to 32 weeks GA; P = .036). These data highlight the substantial differences that small increments of prematurity can have on outcomes in neonates with CHD and may influence future decisions surrounding surgical interventions, medical management, and palliative care. In addition, these mortality rates underscore the need for targeted prenatal care in fetuses with known high-risk CHDs to delay delivery to the latest possible GA.
Our study has several limitations. The KID is an administrative database of only inpatient stays that relies on provider ICD-9-CM coding and is prone to error. Diagnostic codes may not be accurate, which could result in misclassification biases that may affect our birth prevalence and outcomes data. Similarly GA and other important model covariates were based on ICD-9-CM codes. With respect to GA, the method of dating is not known and we cannot verify accuracy. We are not aware of any previous studies that have validated the use of ICD-9-CM codes for GA by week in very and extremely premature infants, and it is possible that inaccurate coding may bias our data. Most other model covariates are typically well-coded administrative variables and should be accurate (ie, race, sex, year of birth, hospital teaching status) with the notable exception of SGA status, which was less prevalent in our analysis (5.9%) than has been reported in prior studies and could reflect suboptimal coding of this variable by providers. Also important to note, data outside of the hospitalization are not captured by the KID and readmissions/transfer data are not tracked across patients; therefore, for our epidemiologic analysis, we are missing information on neonates who were diagnosed outside of a birth hospitalization or who were undiagnosed until after transfer to a congenital heart center. Similarly, for our outcomes analysis, we may underestimate mortality by "double counting" patients readmitted in the first month of life. These factors likely impact the birth prevalence and outcomes of CHDs in term infants but are less of a concern for the premature cohort because these neonates typically have an extended birth hospitalization. Term neonates are also likely less accurately classified because our definition of "term" relied upon a diagnosis of exclusion (ie, no documented ICD-9 prematurity code). In addition, mortality rates represent inhospital mortality only and do not account for mortality in infants sent home with palliative care, infants who died outside of the hospital after discharge, or who died before being transferred to a more advanced pediatric facility for care. We also were unable to ascertain the cause of death including those that may have had an operative mortality. Another limitation is the lack of maternal risk factor data in the KID, which prevented inclusion of these variables as covariates in the regression model to calculate the adjusted odds of death. Thus, we could not account for possible confounding variables such as smoking or diabetes status that are both associated with increased probability of death and CHD.
Providers should target interventions aimed at decreasing the likelihood of premature delivery for patients where a CHD is diagnosed in utero as our data highlight that outcomes are substantially improved if delivery can be delayed even by only a few weeks. Future directions include evaluating prematurity-related comorbidities in very and extremely premature infants with CHD and evaluating outcomes after surgical interventions. ■ Submitted for publication Jun 14, 2016 ; last revision received Aug 11, 2016; accepted Oct 7, 2016 Figure. Odds of severe CHD in very/extremely premature infants vs term infants. AV, atrioventricular; TAPVR, total anomalous pulmonary venous return; TGA, transposition of the great artery. 
